Immix Biopharma (IMMX) Gains from Investment Securities (2020 - 2026)

Immix Biopharma has disclosed Gains from Investment Securities across 7 years of filings, most recently posting -$34153.0 for Q1 2026.

• Gains from Investment Securities for Q1 2026 came in at -$34153.0, down 100.83% year-over-year; the trailing twelve-month figure through Dec 2025 was $5.3 million (up 234.83% YoY), and the FY2025 annual result was $5.3 million, up 234.83% from the prior year.
• Gains from Investment Securities came in at -$34153.0 for Q1 2026 at Immix Biopharma, down from $5.3 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $5.3 million in Q4 2025 to a low of -$34153.0 in Q1 2026.
• The 5-year median for Gains from Investment Securities is $1.3 million (2022), against an average of $1.5 million.
• Across the five-year window, Gains from Investment Securities jumped 46183.38% in 2025 and slumped 100.83% in 2026, its largest moves.
• Immix Biopharma's Gains from Investment Securities stood at $1.8 million in 2022, then soared by 41.85% to $2.5 million in 2023, then sank by 37.43% to $1.6 million in 2024, then jumped by 234.83% to $5.3 million in 2025, then plunged by 100.65% to -$34153.0 in 2026.
• The last three Gains from Investment Securities figures came in at -$34153.0 (Q1 2026), $5.3 million (Q4 2025), and $21760.0 (Q3 2025), per Business Quant data.